&lt;p&gt;Aloperine Exerts Antitumor Effects on Bladder Cancer in vitro&lt;/p&gt;

Zhang, Lijun; Liang, Jun; Liu, Xiaohua; Wu, Jianhua; Tan, Daqing; Hu, Wei

doi:10.2147/ott.s260215

Cited by 11 publications

(4 citation statements)

References 42 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Studies revealed that ALO could reverse cisplatin resistance in colorectal cancer cells by inhibiting HIF-1α/ ERK pathway (Zheng et al, 2020). Moreover, ALO was reported to protect human epithelial cells against oxidative stress and apoptosis via regulating Nrf2/HO-1 signaling pathway (Zhang et al, 2020). In addition, ALO protected myocardial injury in rats via activation the PI3K/Akt pathway (Mao et al, 2019).…”

Section: Discussionmentioning

confidence: 99%

Aloperine inhibits RANKL-induced osteoclast differentiation via suppressing the MAPK signaling pathways

Wang

et al. 2023

Qual. Assur. Saf. Crops Foods

View full text Add to dashboard Cite

To figure out the molecular mechanism of aloperine (ALO) on receptor activator of nuclear factor (NF)-kappa-B (κb) ligand (RANKL)-caused osteoclast differentiation. The histopathological analysis and tartrate-resistant acid phosphatase (TRAP) staining assays were applied to check the extent of bone loss of the femur. Then, the protein expressions of nitric oxide synthase 2, glutathione reductase, nuclear erythroid 2-related factor 2, heme oxygenase-1, nicotinamide adenine dinucleotide phosphate (NADPH) oxidase 1, and catalase were checked in RAW264.7, a macrophage cell line, by enzyme-linked-immunosorbent serologic assay and Western blot analysis. Further, the TRAP staining and quantitative polymerase chain reaction assay were applied to characterize the level of RAW264.7 osteoclast differentiation. Besides, Western blot assay was used to check the protein expressions of extracellular regulated protein kinases (ERK), c-Jun N-terminal kinase (JNK), and P38 in RAW264.7. Finally, ERK activation blocker U0126 was used to inhibit mitogen-activated protein kinase (MAPK) signaling pathway to determine the effect of MAPK signaling pathway on RAW264.7 osteoclast differentiation. In this study, the results demonstrated that ALO could inhibit lipopolysaccharide-induced bone loss in vivo in a dose-dependent man-ner, with significant inhibitory effects at high doses. Further research indicated that ALO could inhibit RANKL-induced oxidative stress and osteoclast differentiation of RAW264.7. Then, ALO could inactivate MAPK signaling pathway. Finally, the results showed that inhibition of MAPK signaling pathway could increase ALO inhibition of RANKL-caused osteoclast differentiation. ALO inhibits RANKL-caused osteoclast differentiation by suppressing the MAPK signaling pathways.

show abstract

Section: Discussionmentioning

confidence: 99%

Aloperine inhibits RANKL-induced osteoclast differentiation via suppressing the MAPK signaling pathways

Wang

et al. 2023

Qual. Assur. Saf. Crops Foods

View full text Add to dashboard Cite

show abstract

“…Therefore, it is crucial to develop effective antiviral drugs against ZIKV. Aloperine, known for its various pharmacological activities in treating cardiovascular diseases 22 and bladder cancer, 41 has emerged as a potential candidate for controlling viral infections. Recent studies have shown that aloperine can inhibit several viral infections, including hepatitis C virus (HCV), HIV‐1, and SARS‐CoV‐2 29,30,42 .…”

Section: Discussionmentioning

confidence: 99%

The in vitro and in vivo antiviral effects of aloperine against Zika virus infection

Zhou

Lao

Long

et al. 2023

Journal of Medical Virology

View full text Add to dashboard Cite

Zika virus (ZIKV) infection poses a significant threat to global public health and is associated with microcephaly. There are no approved ZIKV-specific vaccines or drugs for the clinical treatment of the infection. Currently, there are no approved ZIKV-specific vaccines or drugs for the clinical treatment of the infection. In this study, we investigated the antiviral potential of aloperine, a quinolizidine alkaloid, against ZIKV infection in vivo and in vitro. Our results demonstrate that aloperine effectively inhibits ZIKV infection in vitro, with a low nanomolar half maximal effective concentration (EC 50 ). Specifically, aloperine strongly protected cells from ZIKV multiplication, as indicated by decreased expression of viral proteins and virus titer. Our further investigations using the time-of-drug-addition assay, binding, entry, and replication assays, detection of ZIKV strand-specific RNA, the cellular thermal shift assay, and molecular docking revealed that aloperine significantly inhibits the replication stage of the ZIKV life cycle by targeting the domain RNAdependent RNA polymerase (RDRP) of ZIKV NS5 protein. Additionally, aloperine reduced viremia in mice and effectively lowered the mortality rate in infected mice.These findings highlight the potency of aloperine and its ability to target ZIKV infection, suggesting its potential as a promising antiviral drug against ZIKV.

show abstract

“…Bladder cancer is the most common malignant tumor of the urinary system and is rated as the tenth most common form of cancer and the ninth leading cause of cancer-associated mortality worldwide in 2018, occurring in the mucous membrane of the bladder tissues (1,2). In china, its incidence ranks first among urogenital system tumors (3).…”

Section: Introductionmentioning

confidence: 99%

Lamin B2 contributes to the proliferation of bladder cancer cells via activating the expression of cell division cycle‑associated protein 3

Chen

et al. 2022

Int J Mol Med

View full text Add to dashboard Cite

Bladder cancer is the most common malignant tumor of the urinary system, and in China it is first among urogenital system tumors. More therapeutic targets are still urgently required to combat this disease. Lamin B2 (LMNB2) is a type of nuclear lamina filament protein, which is involved in multiple cellular processes, and known as an oncogene affecting the progression of multiple types of cancers. Although the multiple effects of LMNB2 on cancer progression have been elucidated, its possible role in bladder cancer remains unclear. In the present study, it was determined that LMNB2 expression was upregulated in human bladder cancer tissues, and its expression was correlated with the prognosis and the clinical features, including tumor stage (P=0.001) and recurrence (P= 0.006) of patients with bladder cancer. In addition, it was further revealed that LMNB2 depletion inhibited bladder cancer cell proliferation, stimulated cell cycle arrest and apoptosis in vitro, and suppressed tumor growth of bladder cancer cells in mice. Furthermore, the present data revealed that LMNB2 promoted the proliferation of bladder cancer cells via transcriptional activation of CDCA3 expression. Therefore, the role of LMNB2 in bladder cancer progression was demonstrated, and may serve as a promising therapeutic target for bladder cancer treatment.

show abstract

<p>Aloperine Exerts Antitumor Effects on Bladder Cancer in vitro</p>

Cited by 11 publications

References 42 publications

Aloperine inhibits RANKL-induced osteoclast differentiation via suppressing the MAPK signaling pathways

Aloperine inhibits RANKL-induced osteoclast differentiation via suppressing the MAPK signaling pathways

The in vitro and in vivo antiviral effects of aloperine against Zika virus infection

Lamin B2 contributes to the proliferation of bladder cancer cells via activating the expression of cell division cycle‑associated protein 3

Contact Info

Product

Resources

About